Stem Cell-Derived Microvesicles via 3D Culture for Stroke Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using mesenchymal stem cells in therapeutic applications face challenges such as tumor formation risk, cerebral infarction due to cell size, limited brain penetration in chronic stages, and limited specialization propensity, while methods for isolating and enhancing stem cell-derived microvesicles for clinical use are not well established, hindering their development as medicinal products.
Innovation Solution
Stem cells are dynamically 3-dimensionally cultured or ischemically stimulated using a PEG hydrogel microwell array to promote the production of microvesicles with enhanced microRNA expression levels, specifically miR-137, miR-184, and miR-210, which are then used to enhance neurogenesis and angiogenesis effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are used for therapeutic applications, then therapeutic effects are achieved, but tumor formation risk increases
Solution Approach 1:
The patent extracts and utilizes microvesicles secreted by stem cells, which carry therapeutic factors (microRNAs, proteins, lipids) without the risks associated with whole cell transplantation. This separates the beneficial paracrine effects from the harmful potentials of cell engraftment.
Solution Approach 2:
The patent uses microvesicles as a copy or surrogate of stem cell therapeutic function. These microvesicles replicate the paracrine signaling capabilities of stem cells without requiring actual cell transplantation, thereby achieving therapeutic effects while eliminating cell-related risks.
2Reliability
If stem cells are transplanted, then therapeutic effects are achieved, but cerebral infarction may occur due to artery occlusion from large cell size
Solution Approach 1:
The patent extracts the therapeutic functional components (microvesicles) from whole stem cells. These microvesicles are nanoscale particles that can circulate freely in blood vessels without causing mechanical occlusion, eliminating the artery blockage risk while retaining therapeutic capabilities.
Solution Approach 2:
The patent changes the size parameter from whole stem cells (large) to microvesicles (nanoscale 0.1-1 μm). This size reduction enables safe circulation through cerebral vasculature while maintaining therapeutic functionality through enriched microRNA content.
3Reliability
If stem cells are used in chronic stage, then therapeutic effects are limited, but this is due to limited brain penetration caused by large cell size
Solution Approach 1:
The patent changes the size parameter from whole stem cells to nanoscale microvesicles. This size reduction enables effective brain penetration in chronic stroke stages where the blood-brain barrier is more intact, allowing microvesicles to reach target tissues that larger cells cannot access.
4Ease of operation
If conventional 2D culture methods are used, then ease of operation is maintained, but production of microvesicles with therapeutic microRNAs is insufficient
Solution Approach 1:
The patent transitions from conventional 2D culture to 3D culture system. This dimensional change creates a more physiologically relevant environment that significantly enhances microvesicle production and microRNA enrichment while maintaining operational feasibility through established 3D culture protocols.
Solution Approach 2:
The patent applies ischemic stimulation as a cultural parameter modification. By subjecting stem cells to controlled ischemic conditions in 3D culture, the system triggers enhanced microvesicle secretion with elevated therapeutic microRNA content, thereby increasing productivity without complicating the overall process.
Data Source
AI summary
The present invention relates to stem cell-derived microvesicles with enhanced efficacy, a use thereof, and a method for enhancing efficacy, and more particularly, to a use of stem cell-derived microvesicles with an enhanced expression level of microRNAs for the prevention or treatment of stroke, and a method for promoting the production of microRNAs of stem cell-derived microvesicles and enhancing efficacy, and a method for promoting the production of stem cell-derived microvesicles and microRNAs within the microvesicles and enhancing the efficacy of stem cells and microvesicles thereof by 3-dimensionally culturing or ischemically stimulating stem cells. Since the method according to the present invention has excellent effects capable of promoting the production of stem cell-derived microvesicles and microRNAs in the microvesicles and capable of enhancing the efficacy of stem cells or microvesicles isolated therefrom, it is possible to obtain stem cell-derived microvesicles containing high levels of materials including therapeutic microRNAs efficiently and in large quantities through this, and thus, the microvesicles are expected to be able to be usefully used in related research fields and future clinical settings.